Merck's MK-0616, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Patients with Hypercholesterolemia in Phase 2b Study Pharmaceutical Investing
Voyager Therapeutics to Receive $25 Million Payment for License of Next-Generation AAV Capsids for Multiple Neurologic Disease Targets Pharmaceutical Investing
U.S. FDA Clears Abbott's FreeStyle Libre® 2 and FreeStyle Libre® 3 Sensors for Integration with Automated Insulin Delivery Systems Pharmaceutical Investing
US FDA Approves Intramuscular Administration for Merck's MMRV Family of Vaccines: M-M-RII , VARIVAX , and ProQuad Pharmaceutical Investing
Late-Breaking Data from Landmark COAPT Trial Show Long-Term Benefits of Abbott's MitraClip Device Pharmaceutical Investing
New Data Show Superiority of Abbott's TriClip Device Compared to Medical Therapy for Tricuspid Regurgitation Pharmaceutical Investing
Bristol Myers Squibb Receives European Commission Approval of Reblozyl® for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia Pharmaceutical Investing
Merck and AstraZeneca Provide Update on US Regulatory Review of LYNPARZA® for Use in Combination With Abiraterone and Prednisone or Prednisolone for the Treatment of Metastatic Castration-Resistant Prostate Cancer Pharmaceutical Investing
Resverlogix Announces New Research Highlighting Apabetalone's Potential Benefits in Cardiovascular Disease, Heart Failure, and COVID-19 Life Science Investing News
The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor Pharmaceutical Investing
Chronic Cluster Headaches No More: The Promise Of Lobe Sciences' At-Home Psychedelic Treatments Without The Trip! Pharmaceutical Investing
